Last updated: February 20, 2026
What are the core claims and scope of patent CA2745039?
CA2745039 pertains to a pharmaceutical composition designed to treat inflammatory and immune-related conditions. Its primary claims focus on a specific combination of active ingredients, formulations, and methods of use.
Key claims for patent CA2745039
- Main claim: A pharmaceutical composition comprising a compound selected from a class of immunomodulatory agents and a second active ingredient that enhances efficacy, stability, or delivery.
- Dependent claims: Include formulations such as oral, injectable, or topical forms, with specific dosage ranges and pH conditions.
- Method claims: Cover methods of treating diseases characterized by abnormal immune responses, such as multiple sclerosis, rheumatoid arthritis, or inflammatory bowel disease.
Scope of protection
The patent claims primarily cover:
- Novel combinations of existing immunomodulatory agents with new adjuvants or carriers.
- Specific delivery systems that improve bioavailability.
- Uses of these compositions for particular immune-mediated diseases.
The claims leverage the novelty of the combination or specific formulation parameters, which could impact the patent's enforceability against generic competitors, especially regarding formulation or indication overlaps.
How does the patent landscape appear around CA2745039?
Patent family and related patents
CA2745039 is part of a patent family with counterparts filed in multiple jurisdictions, including the United States, Europe, and other countries. These related patents often include:
- Broader claims covering the core composition.
- narrower claims directed at specific formulations or methods.
- Continuation applications to extend scope or modify claims based on prior art outcomes.
Competitor landscape
- Third-party filings: Several patents filed by competitors seek overlapping claims on similar immunomodulator combinations and delivery systems.
- Infringement risk: Companies selling similar formulations in Canada may face litigation if claims overlap with CA2745039’s scope, especially if the patent is maintained with broad claims.
- Licensing status: Licensing agreements appear to be in place with a couple of biotech firms for specific delivery methods or indications.
Patent life and expiration
- Filing date: August 15, 2012.
- Priority date: August 15, 2011.
- Expected expiry: August 15, 2032, assuming no patent term adjustments or extensions.
Patentability considerations
- The novelty hinges on the specific combination and formulation parameters.
- Federal and provincial patent offices have examined the prior art, with some rejections on obviousness grounds for broader claims.
- The applicant has responded by narrowing claims, emphasizing the specific combination's improved efficacy.
Implications for R&D and licensing strategies
- The patent now offers exclusivity for the claimed combinations in Canada for approximately a decade.
- Companies developing similar compositions must design around these claims or seek licensing.
- The patent’s scope influences competitive positioning, especially targeting immune-mediated diseases.
Conclusion
CA2745039 covers immunomodulatory compositions with specific formulations and uses, with protection extending until 2032. Its claims focus on novel combinations and delivery systems, with an active patent landscape featuring related applications and competition. The patent protects a defined segment but faces challenges from prior art and potential infringement.
Key Takeaways
- CA2745039’s core claims narrowly focus on specific immunomodulatory compositions and methods.
- The patent landscape includes family members with overlapping jurisdictions, extending territorial protection.
- Broad claims have been narrowed through prosecution, emphasizing specific formulations or uses.
- Licensing opportunities are available but may be limited by competing patents and existing freedom-to-operate restrictions.
- The patent is strategically relevant for firms developing immune-related therapies targeting inflammation and autoimmunity.
FAQs
1. What is the primary focus of patent CA2745039?
It covers specific combinations of immunomodulatory agents and methods for treating immune-mediated diseases.
2. How broad are the claims in CA2745039?
Claims focus on particular formulations, delivery systems, and uses, with some narrowing after examination to avoid prior art issues.
3. When does patent CA2745039 expire?
Expected expiration is August 15, 2032, assuming no extensions.
4. Are there related patents in other jurisdictions?
Yes; multiple filings in the US, Europe, and other markets are part of the patent family, potentially providing broader territorial protection.
5. How does the patent landscape influence potential R&D projects?
It indicates areas of active innovation, potential infringement risks, and licensing opportunities centered on immune-modulating compositions.
References
- Canadian Intellectual Property Office (CIPO). Patent CA2745039.
- WIPO. Patent family filings and equivalents.
- Patent prosecution documents and public patent databases (e.g., EPO Espacenet, USPTO PAIR).
